Bibliography
- KRAFT S, BIEBER T: Fc epsilon RI-mediated activation of transcription factors in antigen-presenting cells. Int. Arch. Allergy 'minutia. (2001) 125:9–15.
- SUTTON BJ, BEAVIL RL, BEAVIL AJ: Inhibition of IgE-receptor interactions. Br. Med. Bull. (2000) 56:1004–1018.
- CASALE TB: Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis. Am. j Respir. Grit. Care Med (2001) 164:S18–21.
- BUSSE WW: Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am. j Respir. Grit. Care. Med (2001) 164:S12–17.
- CHRISTIE G, BARTON A, BOLOGNESE B et al.: IgE secretion is attenuated by an inhibitor of proteolytic processing of CD23 (Fc epsilonRII). Eur. Immunol. (1997) 27:3228–3235.
- •The underlying justification for this approach.
- BAILEY S, BOLOGNESE B, BUCKLE DR et al.: Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing. Bioorg. Med. Chem. Lett. (1998) 8:23–28.
- BAILEY S, BOLOGNESE B, BUCKLE DR et al.: Selective inhibition of low affinity IgE receptor (CD23) processing. Bioorg. Med. Chem. Lett. (19980 8:29–34.
- BAILEY S, BOLOGNESE B, FALLER A et al.: Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents. Bioorg. Med. Chem. Lett. (1999) 9:3165–3170.
- •The SAR around SB-257702.
- FALLER A: The design of selective inhibitors of sCD23 processing. 11th ESC-SCI Symposium on Medicinal Chemistry Cambridge, UK (September 2001).
- NORMAN P: RSC-SCI Medicinal Chemistry-llth Symposium, 9-12 September 2001., Cambridge UK Idrugs. (2001) 4:1116–1120)
- •The disclosure of SB435466.